Navigation Links
nContact's Cardiac Ablation Technology to be Presented in Two Noteworthy Posters at Boston Atrial Fibrillation Symposium 2012

MORRISVILLE, N.C., Jan. 9, 2012 /PRNewswire/ -- nContact, Inc., the leading innovator in epicardial ablation devices, today announced its technology will be presented by physicians in two posters at the 17th Annual International Boston Atrial Fibrillation Symposium, January 12-14 in Boston, Massachusetts.  nContact will be showcasing its Numeris® Coagulation System with VisiTrax® and next generation EPi-Sense™ Coagulation System at its Boston AF Symposium booth #301.

nContact's epicardial ablation device integrates suction, perfusion and radiofrequency energy to ensure consistent cardiac tissue contact and create visible, continuous lesions on the epicardium of a beating heart. Access to the posterior of the atrium is achieved with unique access through the diaphragm with a SUBTLE (sub-thoracic, total endoscopic) approach for minimally invasive, closed-chest epicardial ablation.  

The technology will be presented in the following posters on Friday, January 13, 2012 available from 7:30 am until 6:30 pm:

  • Poster # 10 titled: "Prospective Reveal® XT Outcomes for the Convergent Atrial Fibrillation Ablation Procedure"
    Evaluates long-term outcomes of a multidisciplinary ablation procedure to treat persistent or longstanding persistent AF, as monitored by Reveal XT technology (Medtronic); presented by Borut Gersak, MD, of University Medical Center Ljubljana, Ljubljiana, Slovenia.
  • Poster #20 titled: "Multicenter Retrospective Outcomes for the Treatment of Atrial Fibrillation Using the Multidisciplinary Convergent Procedure"
    Examines outcomes of closed chest AF ablation procedure on patients with persistent or longstanding persistent AF across four U.S. sites; presented by Dr. Keith Golden of St. Vincent Hospital, Indianapolis, IN.
  • About nContact, Inc.
    nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, non-conductive, continuous, bi-atrial lesions on the epicardium of a beating heart.

    To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures.

    The Numeris™ and EPi-Sense™ Coagulation Systems with VisiTrax® have CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter. For more information, please visit www.ncontactinc.comMedia Contacts

     Beth Rose

    Kimberly MuscaranContact, Inc

    The Ruth Group T (919)655-1566 

    T (646)

    SOURCE nContact, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Ikaria® Commences Global Registration Trial for Bioabsorbable Cardiac Matrix
    2. FDA Approves Mechanical Cardiac Assist Device for Children With Heart Failure
    3. Australias Sporting Clubs Select Cardiac Science AEDs
    4. Roche, ChanTest Collaborate for Preclinical Cardiac Safety Testing of Drug Compounds Using iCell Cardiomyocytes and xCELLigence RTCA Cardio Instrument
    5. MedSolutions Launches Implantable Cardiac Defibrillator Program to Reduce Unnecessary Surgeries
    6. Philips Launches HeartStart FR3 Automated External Defibrillator for Professional Responders Treating Victims of Sudden Cardiac Arrest
    7. MedSolutions Announces Program to Reduce Unnecessary Implantable Cardiac Defibrillator Surgeries
    8. Cardiac Dimensions Announces Presentation of Two-Year Efficacy Data From TITAN Clinical Trial
    9. Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
    10. "Today" Show, "Fox & Friends" Put Spotlight on Sudden Cardiac Arrest
    11. Cardiac Dimensions® Receives CE Mark Approval for Enhanced CARILLON® Mitral Contour System™
    Post Your Comments:
    (Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
    (Date:6/24/2016)... N.J. , June 24, 2016  Collagen ... the design, development and manufacturing of collagen and ... regeneration announced today that Bill Messer ... and Marketing to further leverage the growing portfolio ... medical devices. Bill joins the Collagen ...
    (Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
    Breaking Medicine Technology:
    (Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
    (Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
    (Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
    (Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
    (Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
    Breaking Medicine News(10 mins):